Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Nanotechnology Drug Delivery Systems Market $152 Billion by 2027

The global market for nanotechnology drug delivery systems estimated to become $152 billion by 2027, expanding at a CAGR of 10.3% over the forecast period, driven by its potential in targeted drug delivery, personalized nano-medicinal treatments, including in diagnostics, therapeutics and imaging agents.

  • Nanomedicine and nano delivery systems are a relatively new but rapidly developing science where materials in the nanoscale range are employed to serve as means of diagnostic tools or to deliver therapeutic agents to specific targeted sites in a controlled manner.
    • Nanotechnology offers multiple benefits in treating chronic human diseases by site-specific, and target-oriented delivery of precise medicines. Recently, there are a number of outstanding applications of the nanomedicine (chemotherapeutic agents, biological agents, immunotherapeutic agents etc.) in the treatment of various diseases.
Global Nanotechnology Drug Delivery Systems Market

Nanomaterials are at the cutting edge of the rapidly developing area of nanotechnology. The applications of nanotechnology for drug delivery provides the potential for enhanced treatments with targeted delivery and fewer side effects.

  • Over the last two decades, significant progress has been made in the field of nanomedicine, resulting in a number of products, including therapeutics and imaging agents, enabling more effective and less toxic therapeutic and diagnostic interventions.
    • Due to the advantage of their size, nanospheres have been shown to be robust drug delivery systems and may be useful for encapsulating drugs and enabling more precise targeting with a controlled release.
    • Nanomedicine can be utilized as a valid treatment because the development of the disease occurs at the cellular level. 
      • Although, the enhanced permeability and retention effect is predominantly associated with cancer treatments, the use of nanotechnology for drug delivery is also being applied to infection treatment in light of increasing strains of drug-resistant bacteria. 
  • The ability of nanotechnology to provide targeted drug delivery, improved solubility, extended half life and reduce a drug’s immunogenicity has resulted in the potential to revolutionize the treatment of many diseases.
    • Multifunctional nanoparticles play a very significant role in cancer drug delivery. Nanotechnology is also being used to advance the delivery of drug treatments for heart disease.

Although the number of different type of nanoparticles is increasing rapidly, most can be classified into two major types: organic nanoparticles such as liposomes, dendrimers, carbon nanotubes, emulsions, and other polymers; whereas inorganic nanoparticles such as silica nanoparticles, quantum dots, metal nanoparticles and lanthanide nanoparticles usually contain metals, as a core. 

  • Liposomes are being used as vehicles for drug delivery in different human tumors, including breast cancer. Dendrimers are used in MRI as contrast agents, have aided visualization of various pathological processes.
  • Conjugated with pharmacological agents and targeting molecules, organic nanovectors are potent vehicles for drug delivery and selective imaging of different human cancers. 
    • Metallic, organic, inorganic and polymeric nanostructures, including dendrimers, micelles, and liposomes are frequently considered in designing the target-specific drug delivery systems. 
      • In practice, gold nanoparticles are the most commonly used nanoparticles for diagnostics and drug delivery. In particular, the drugs having poor solubility with less absorption ability are tagged with these nanoparticles.
  • However, many problems related to selective binding, targeted delivery and toxicity need to be overcome. Limited knowledge about the toxicity of nanoparticles is a major concern and certainly deserves more attention.
Nanotechnology Drug Delivery Systems Market

The global market for nanotechnology drug delivery systems report provides market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).

The global nanotechnology drug delivery systems market segmented by technology [nanocrystals, nanoparticles (dendrimers, gold nanoparticles, fullerenes, others), liposomes, micelles, nanotubes, others (nanoemulsions, lipid colloidal dispersion, virosomes, polymer
therapeutics, etc.)], application [anti-infectives, anti-inflammatory, cardiovascular, neurology, oncology, others (hematology, ophthalmology)], and geography.

  • Among the nano technologies, the nanoparticles segment accounted for the largest share of the total nanotechnology drug delivery devices market. The potential nanoparticles used in pharmaceutical drug delivery systems include dendrimers, gold nanoparticles, fullerene, and other metal nanoparticles.
    • The dendrimers sub-segment dominated the global nanoparticles market, whereas the gold nanoparticles sub-segment anticipated to register highest CAGR during the forecast period.
      • Factors driving the growth of dendrimers technology market include its unique properties such as polyvalency, flexibility in size and shape, monodispersity, biocompatibility and better transfection abilities than other technologies.
        • The gold nanoparticles are widely used in biomedical science including tissue/tumor imaging, drug delivery, photothermal therapy and immunochromatographic identification of pathogens in clinical specimens using surface plasmon resonance (SPR).
  • On the other hand, the nanotubes segment predicted to witness the fastest double-digit growth rate during the next few years, as these carbon nanotubes (CNTs) are likely to provide high efficiency in drug delivery, biosensing methods for disease treatment and healthcare monitoring, in general.

The global market for nanotechnology drug delivery systems research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Geographically, the North America region led the total nanotechnology drug delivery devices market, closely followed by the Europe region, owing to availability of advanced healthcare infrastructure, presence of large number of prominent biopharmaceutical companies and accelerated approvals of innovative technologies in the developed regions.
    • However, the emerging Asia Pacific and Latin America nanotechnology drug delivery systems markets anticipated to grow at the fastest double-digit rate in the coming years, due to increasing prevalence of chronic diseases, improving healthcare infrastructure, rising disposable income and presence of large pool of generic drug manufacturers in the emerging countries.

The global market for nanotechnology drug delivery systems report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global market for nanotechnology drug delivery systems and included in this report are AbbVie, Inc., Amgen, Inc., Bayer AG, Celgene Corporation, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer, Inc., Roche Holding AG (F. Hoffmann-La Roche AG), Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

  • Technology
    • Nanocrystals
    • Nanoparticles
      • Dendrimers
      • Gold Nanoparticles
      • Fullerenes
      • Others
    • Liposomes
    • Micelles
    • Nanotubes
    • Others (Nanoemulsions, Lipid Colloidal Dispersion, Virosomes, Polymer Therapeutics, etc.)
  • Application
    • Anti-infectives
    • Anti-inflammatory
    • Cardiovascular
    • Neurology
    • Oncology
    • Others (Hematology, Ophthalmology, etc.)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AbbVie, Inc.
    • Amgen, Inc.
    • Bayer AG
    • Celgene Corporation
    • Elan Corporation
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Roche Holding AG (F. Hoffmann-La Roche AG)
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]